Adverse events and concomitant medication information are collected throughout the trial periods, including the safety followup
Tirzepatide, like other agents in this class, requires monitoring for dehydration and potential effects on diabetic retinopathy, particularly during rapid improvement in glucose control
After 72 weeks: Participants taking 5 mg of tirzepatide lost 15% of their starting body weight on average Those taking 10 mg lost an average of 19.5% Those taking the highest dose, 15 mg, lost an average of 20.9% Another phase 3 clinical trial studied the efficacy of once-daily orforglipron in people with obesity and found that it resulted in significant weight loss compared to placebo
Gradual decline
What we dont yet know Long-term cardiovascular outcomes
For the mainstream market, however, the risk has become prohibitive: compounders now face active lawsuits from both Novo and Lilly, permanent injunctions, and FDA sanctions that include criminal referrals